5-Amino-1MQ: Research, Dosing, Side Effects, and Half-Life

What is 5-Amino-1MQ?

5-Amino-1MQ is a small-molecule inhibitor of the enzyme NNMT, studied in animals for its effect on fat tissue and energy metabolism.

The full name behind the shorthand is 5-amino-1-methylquinolinium. It is not a peptide. It is a small molecule built on a quinoline ring, and it belongs to a class of compounds designed to sit inside NNMT and stop that enzyme from doing its job (Neelakantan et al., Biochem Pharmacol 2018, PMID 29155147). It gets listed alongside research peptides because the labs and vendors that study metabolic peptides also study it, and because the outcome researchers care about, fat metabolism, overlaps with why people look at peptides like tesamorelin or MOTS-c. But chemically it is a different kind of molecule.

The honest headline is the size of the evidence base. 5-Amino-1MQ has been tested in cell cultures and in mice. It has not been tested in a published, results-reported human trial. It is not approved by any regulator for any use. As of this writing, no completed human study of 5-Amino-1MQ appears in the public trial record. So when you read a claim about what it "does," the right question is always: in what, a dish, a mouse, or a person? For 5-Amino-1MQ the answer so far is a dish or a mouse.

How does 5-Amino-1MQ work?

Research describes 5-Amino-1MQ as blocking the enzyme NNMT, which in turn is reported to raise two important cell molecules, NAD+ and SAM, and to shift fat cells away from storing fat.

Start with the enzyme it targets. NNMT (nicotinamide N-methyltransferase) takes a methyl group from a molecule called SAM (S-adenosylmethionine) and attaches it to nicotinamide, which is a form of vitamin B3 and a building block for NAD+ (Roberti et al., Mol Metab 2021, PMC7868988). That single reaction sits at a busy crossroads. It uses up SAM, the cell's main methyl donor, and it uses up nicotinamide, which the cell needs to make NAD+. NAD+ is the coenzyme cells rely on to burn fuel and run their energy machinery. A review describes NNMT as directly linking one-carbon metabolism with a cell's methylation balance and its NAD+ level (Roberti et al., Mol Metab 2021, PMC7868988).

Now the logic of blocking it. If NNMT is overactive in fat tissue, it keeps draining nicotinamide and SAM, which can lower NAD+ and change how fat cells behave. The idea researchers tested is that turning NNMT down should let NAD+ and SAM rise again and push fat cells toward burning fuel rather than storing it. The founding small-molecule study reported exactly that pattern in fat cells: 5-Amino-1MQ raised intracellular NAD+ and SAM and lowered the NNMT product 1-methylnicotinamide, and it suppressed fat-building activity in adipocytes (Neelakantan et al., Biochem Pharmacol 2018, PMID 29155147).

There is also strong upstream evidence that NNMT is a real metabolic target, separate from any one drug. An earlier study knocked down the NNMT gene in the white fat and liver of mice and reported that this protected the animals against diet-induced obesity by raising cellular energy expenditure, along with better glucose handling and less fatty liver (Kraus et al., Nature 2014;508:258-262, PMID 24717514). That paper did not use 5-Amino-1MQ. It used genetic knockdown. But it is the reason the field believes dialing NNMT down could matter for metabolism, and it is why a drug that blocks NNMT drew interest in the first place. Whether the same biology plays out in humans is still an open question, because the human step has not been done.

What does research report on 5-Amino-1MQ?

The reported effects are body-weight and fat-mass reductions in obese mice, plus fat-cell changes in culture. No benefit has been demonstrated in humans, because no human trial exists.

The central finding comes from the founding study. In mice made obese on a high-fat diet, Neelakantan et al. reported that 5-Amino-1MQ reduced body weight versus saline controls, decreased white fat mass (measured as epididymal fat-pad weight), shrank adipocyte size, and lowered plasma total cholesterol (Neelakantan et al., Biochem Pharmacol 2018, PMID 29155147). One detail is worth pulling out, because it is the part that gets people's attention: the authors reported that the weight change happened without a drop in total food intake, which points to a metabolic mechanism rather than simple appetite suppression. That is a meaningful contrast with appetite-driven metabolic compounds.

The mechanism-level work sits underneath that result. In adipocytes, the compound raised NAD+ and SAM and reduced 1-methylnicotinamide, consistent with NNMT being blocked, and it suppressed lipogenesis, the process by which cells build and store fat (Neelakantan et al., Biochem Pharmacol 2018, PMID 29155147). The gene-knockdown study adds independent support that the target is real: removing NNMT activity in fat and liver protected mice from diet-induced obesity and improved glucose tolerance (Kraus et al., Nature 2014;508:258-262, PMID 24717514).

Now the part that has to be stated plainly. None of this has been shown in people. There is no published human trial of 5-Amino-1MQ reporting weight loss, fat loss, or any clinical outcome. The compound has not completed the human testing that would tell you whether the mouse results carry over, at what dose, or with what safety profile. So the correct framing for a reader is that the interesting data are entirely preclinical, and the leap from "worked in mice" to "works in humans" is exactly the leap that has not been made. Many compounds that looked strong in obese mice have failed or underwhelmed in humans, so the mouse data are a reason for research interest, not a promise of a result.

What dosing does 5-Amino-1MQ research report?

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

Two facts frame this section plainly. First, the only real dosing data for 5-Amino-1MQ come from mice, and they are given in milligrams per kilogram per dose, a unit that does not convert to a fixed human dose. Second, there is no established human dose, because there is no human trial. Any "protocol" you see circulating for people is not derived from a completed human study. The table shows what the actual published study used, with its source.

Because the figure is a mouse mg/kg number, scaling it to a person is not valid; body-size scaling between species is not a simple multiplication, and that is a core reason the human dose is truly unknown. A separate note on unit math, shown generically as a reference and not as an instruction to dose: a milligram amount only maps to a syringe or capsule reading after you know the concentration. As a generic example unrelated to any recommendation, if a solution holds 10 mg per 1 mL, then a U-100 insulin syringe (which reads 100 units per mL) would show 1 mg as 10 units on that scale. That is arithmetic for reading a label, not guidance to take anything. One more practical note: some vendors sell 5-Amino-1MQ as an oral capsule and others as a powder, and the two are not interchangeable at the same number, another reason a single "dose" figure is misleading. For related reading see /reconstitution.

What are the side effects of 5-Amino-1MQ?

Because there is no human trial, the human side-effect profile of 5-Amino-1MQ is unknown; the only safety signal is that mice tolerated it in short studies without reported overt adverse effects.

This is the most important honesty check on the page. There is no human safety database for 5-Amino-1MQ the way there is for an approved drug, because it has not been through human testing. In the founding mouse study, the authors reported that NNMT inhibition did not produce observable adverse effects at the dose used and did not suppress food intake, but that is short-term tolerability in rodents, not a human safety guarantee (Neelakantan et al., Biochem Pharmacol 2018, PMID 29155147). Animal tolerability tells you a compound is worth studying further; it does not tell you what happens in a person over weeks or months.

There are also reasons for theoretical caution that come straight from the mechanism. NNMT influences the cell's methylation balance and NAD+ pool, and the same enzyme has been studied in the context of cancer biology and other tissues, so changing its activity broadly is not automatically harmless (Roberti et al., Mol Metab 2021, PMC7868988; Sun et al., Front Pharmacol 2024, PMC11196770). This is not a claim that 5-Amino-1MQ causes harm; it is a statement that a molecule which touches a pathway this central deserves real human safety data before anyone assumes it is benign, and that data does not exist yet. Two general points apply to any research compound: purity varies between suppliers, so a certificate of analysis is worth reviewing (see /coa), and unknown long-term effects are exactly that, unknown.

What is the half-life of 5-Amino-1MQ?

There is no published human half-life for 5-Amino-1MQ; the dosing schedule used in the founding mouse study (repeated daily subcutaneous dosing) implies a short duration of action in that model, but no formal human pharmacokinetic study has been reported.

Half-life is the time it takes the body to clear half of a compound, and it usually comes from pharmacokinetic studies that sample blood over time. For 5-Amino-1MQ, no such human study has been published, so a specific human half-life number would be a guess. What the record does show is indirect: the mouse work used repeated dosing across the study period rather than a single injection, which is consistent with a molecule that does not persist for long and needs to be given regularly to keep its effect (Neelakantan et al., Biochem Pharmacol 2018, PMID 29155147). Treat any exact half-life figure you see quoted for humans with skepticism, because there is no human PK paper to support it.

How does 5-Amino-1MQ compare to other metabolic research compounds?

5-Amino-1MQ is a small-molecule NNMT inhibitor with only mouse data, which sets it apart from metabolic peptides and drugs that have actual human trials.

The useful contrast is evidence level, not marketing. A compound like MK-677 (ibutamoren), an oral ghrelin mimetic, has a randomized human trial: fat-free mass rose about 1.1 kg over 12 months, but fasting glucose rose and insulin sensitivity fell at 25 mg/day (Nass et al., Ann Intern Med 2008;149(9):601-611). Whatever you make of that result, it is human data, with measured tradeoffs. 5-Amino-1MQ has nothing comparable in humans. It is at an earlier stage entirely. So if someone frames 5-Amino-1MQ as an "oral fat-loss compound" next to peptides that carry human evidence, the honest correction is that it sits a full research phase behind them. For peptides with more human context in the metabolic space, see /mots-c and /tesamorelin, and for the broader category see /what-are-peptides.

Contraindications and cautions

Because 5-Amino-1MQ has no human trial, no evidence-based contraindications exist; the practical caution is that it is unstudied in people and unapproved.

There is no clinical guidance for who should avoid 5-Amino-1MQ, because the studies that would produce such guidance have not been done. That absence is itself the caution. A few plain points follow from the mechanism and the state of the evidence. The compound alters a pathway (NNMT, NAD+, and methylation) that is active across many tissues, and that pathway has been studied in cancer and other contexts, so broad claims of safety are not supported (Roberti et al., Mol Metab 2021, PMC7868988). Anyone with an existing health condition, or taking other medicines, has no human interaction or safety data to rely on here. This page is educational; decisions about any research compound belong with a qualified clinician, not a product page.

Common mistakes and misconceptions

The biggest mistake is reading mouse results as if they were human results. Below are the traps that show up most often.

• Treating "reduced weight in obese mice" as proof it causes weight loss in people. It has not been tested in people (Neelakantan et al., 2018, PMID 29155147).
• Assuming an oral capsule form has an established human dose. There is no human dosing study, so the number on a label is not clinically validated.
• Believing "no side effects" because a short mouse study reported none. Short-term rodent tolerability is not a human safety profile.
• Confusing the gene-knockdown evidence with drug evidence. The Nature 2014 knockdown result validates NNMT as a target; it does not test 5-Amino-1MQ (Kraus et al., 2014, PMID 24717514).
• Quoting a specific human half-life. No human pharmacokinetic study of 5-Amino-1MQ has been published.